



AIHEALTHCARE SECTOR REPORT

Q1 2025

PALA IS THE NO. 1 PARTNER TO FAST GROWING COMPANIES

PARTNER LED ADVISORY BOUTIQUE

CORPORATE FINANCE MANDATES

+30 M&A transactions closed























SERIAL ENTREPRENEURS WITH STRONG EXPERIENCE

We focus on industries where we possess deep industry expertise gained through our own founding experience or successfully closed transactions



Technology






Training & Education



Healthcare







STARTUP MANDATES





Total financing volume





FUSE-AI











WHY WE ARE DIFFERENT











Joh-€=las



We are entrepreneurs

We found companies

We act as business angel

We have large cap experience

We are success driven



ABOUT US



PALA is an independent financial advisor established to identify, service and execute transactions across high-growth sectors

PALA provides advice on mergers and acquisitions, strategic consulting, capital raising and corporate finance

The firm serves venture capital, private equity, startups, and family-owned business worldwide. For more information

LEARN MORE ABOUT PALA

LEARN MORE ABOUT OUR SERVICES

LEARN MORE ABOUT OUR MANAGING PARTNERS

REQUEST A MEETING

KEY FACTS AND FIGURES

ENTREPRENEURS INNOVATIVE

5 *Total Professionals*

+30
Transactions
Completed

+20 Years of Experience +€2BN

Transaction

Volume

60% Cross-border Deals

OUR SERVICES

EXPERIENCED

M&A



- Sell side
- Buy side
- MBI/MBO

DEBT ADVISORY



- Structuring of debt and equity
- Capitalization
- Venture debt

BUY AND BUILD



- Consolidation Strategy
- Market research & Approach

SUCCESSION



- Sale preparation
- Deal structuring

CORPORATE VENTURE CAPITAL (CVC)



- Startup research
- advisory & management

VALUATION



- Forecast & company valuation
- Fairness opinion

SELECTED REFERENCES

























AI HEALTHCARE LANDSCAPE IN EUROPE

IMAGING & DIAGNOSTICS



DRUG DISCOVERY



REMOTE MONITORING



GENOMICS









HOSPITAL DECISION SUPPORT





♦ ₩₩

VIRTUAL ASSISTANT







CLINICAL TRIALS



NUTRITION





MENTAL HEALTH









COMPLIANCE











AI IS REVOLUTIONIZING HEALTHCARE M&A AND FUNDRAISING

FUNDRAISING & M&A SPLIT

Digital Al Healthcare system in Europe is maturing with many ventures reaching the scale necessary to attract significant investment DACH **IRELAND** Nordics Spain Others

M&A TRANSACTION ENVIRONMENT

Increasing M&A activity is driven by strategic players pursuing acquisitions to integrate advanced Al capabilities. Strategic acquisitions have become crucial for larger players seeking to scale their operations Transaction Count Disclosed Value in \$m Q3 Q4

FUNDRAISING ENVIRONMENT

Fundraising activity in Europe is heating up as Al is no longer a futuristic concept. Al is reshaping the healthcare industry and venture funds understanding the importance of this sector **Fundraising Count** Disclosed Value in \$m 20 67 67 35 30 68 145 760 192 80 623 Q4 Q1 Q2 Q3



SELECTED M&A DEALS IN EUROPE



UNDISCLOSED ACQUIRED BY

surgicalscience

- Surgical Science acquires Intelligent Ultrasound for an undisclosed amount
- The acquisition is a strategic move by Surgical Science, to enhance its portfolio with Intelligent Ultrasound's advanced ultrasound simulation and artificial intelligence products.

February 2025



\$688M ACQUIRED BY



- Biotech firm Recursion has acquired Exscientia for \$688M in an all-stock deal
- UK-based Exscientia also operates an Alpowered drug discovery platform and is developing a pipeline of treatments for immunology and oncology

November 2024



UNDISCLOSED ACQUIRED BY



- Revenio Group has acquired Thirona Retina BV from Thirona for an undisclosed amount
- By joining forces with Revenio, a market leader in eye care solutions, Thirona Retina is poised to enhance patient outcomes and drive innovation in eye care.

August 2024



\$92.4M ACQUIRED BY

SAMSUNG MEDISON

- Samsung Medison has acquired France-based fetal ultrasound artificial intelligence software company for \$92.4M
- Sonio's Al expertise and Samsung Medison's cutting-edge ultrasound systems will launch breakthrough Al workflows that enhance patient outcomes
 August 2024



UNDISCLOSED HERA ACQUIRED BY biotech

- Hera Biotech acquires several assets and associated IP of single-cell and Al-driven biomarker discovery company Scailyte
- Hera's initial product—developed with Scailyte's deep sequencing platform—will launch in the US fertility market in late 2024

January 2024



€77M ACQUIRED BY



- Olympus has acquired UK-based leader in Al for cancer detection for €77M
 - The acquisition strengthens Olympus' initiatives in digital health and brings the promise of Apowered real-time diagnosis and minimally invasive treatment closer to reality

December 2022



SELECTED FUNDRAISING IN EUROPE



\$600M N/A



- Alphabet Spin-off Al drug discovery startup has raised €600M in its first external funding round
- Isomorphic Labs will use the proceeds to advance its AI research and development focusing on its next generation AI drug design engine

March 2025



€5M SEED








- Germany-based pioneer in digital first fertility care has raised 5M in its seed funding round
- The Seed funding will fuel the expansion of Ovum Care's groundbreaking services across Europe

April 2024





\$23M SERIES A



- French deeptech startup has raised €23M in a Series A round. The round follows an €8M preseed investment in December 2023
- Spore.Bio develops microbiological testing to detect contamination. Proceeds will be used to accelerate its industrial rollout

February 2025



€23M SERIES C



- Germany-based leading technology providers in the field of medical reporting has raised €23M led by TCM Capital Life Science
- Funding will be primarily used to expand product development and international partnerships to strengthen presence in NA and Australia

April 2024



\$73M SERIES B



- Switzerland-based Al-powered protein engineering platform Cradle has raised \$73M led by silicon based IVP
- Series B funding will enable Cradle to expand its in-house wet lab generating additional datasets to train its models for more complex challenges
 November 2024

diabeloop

€15M SERIES C COMPLEMENT

Existing Investors

- French-based developer of automated Type 1 diabetes treatment technologies has raised €15M as a complement to its €70M Series C round closed in 2022
- Fundraising will be primarily used to accelerate revenue growth

March 2024



OUR TEAM FOR YOUR SUCCESS

PALA CORE TEAM



PATRICK BAUER

Managing Partner

Patrick founded **PALA** in 2021 with the vision to provide topnotch advice to entrepreneurs from future - oriented sectors

Patrick is a serial entrepreneur with a strong background in the investment banking industry. Prior to founding PALA, Patrick served as a Vice President at Ferber & Co.



LAURENS AHLRING

Managing Partner

Laurens founded **PALA** in 2021 with the vision to revolutionize the investment industry through innovative approaches.

Prior to PALA he worked in the Investment Banking industry, which equipped him with a strong financial experience and most recently he founded his own startup.



VALERIIA BAZHANOVA

Associate

Valeriia acts as Associate for **PALA** and is responsible for the execution of M&A transactions and startup projects.

Prior joining PALA, she worked for the leading accounting firm Mazars. Valeriia holds a Bachelor of Science in Leadership Management and has a background in accounting.

INDUSTRY EXPERTS



MORITZ MÜHLECK

Industry Expert

Moritz is a member of the advisory board and a renowned entrepreneur in the fitness and leisure industry.

As founder and CEO of the fitness chain Fit/One he has made a significant contribution to the company's success since 2014.



FRANK AHLRING


Financing Expert

Frank has been working in the financing industry for over 40 years and acts as financing expert to PALA

Prior to starting his own financing advisory Frank worked in the Corporate Banking division of Commerzbank Bremen.



TRENDS PALA EXPECTS FOR 2025



DIGITAL TRANSFORMATION

01

Artificial intelligence remains at the cornerstone of healthcare innovation, with industry leaders investing heavily in advanced Al-driven technologies to not only streamline processes but also enhance diagnostic accuracy, improve patient outcomes, and optimize resource allocation across the entire healthcare ecosystem

REGULATORY AND COMPLIANCE DYNAMICS

02

As Al becomes more integral to healthcare, adhering to data protection regulations like HIPAA in the United States and GDPR in Europe—alongside emerging Al-specific guidelines—grows increasingly vital. Consequently, many mergers and acquisitions target organizations that demonstrate strong data governance and compliance capabilities

CONSOLIDATION AND STRATEGIC ACQUISITIONS

03

Healthcare conglomerates and tech giants increasingly acquire niche Al firms to fill gaps in their digital offerings, accelerate innovation, and boost competitiveness. Strategic M&A enables rapid integration of advanced Al—whether for imaging, predictive analytics, or personalized medicine—without starting from scratch.

INVESTMENT AND FINANCIAL TRENDS

04

Robust venture capital funding in Al healthcare startups has made them appealing acquisition targets for larger entities seeking to expand their technology portfolios. At the same time, the prospect of high returns is drawing private equity firms to increasingly invest in or acquire businesses that operate at the intersection of Al and healthcare.



PRIVATE AND PALA REFERENCES


















































CORPORATE FINANCE STRATEGIC ADVICE SCALE-UP

palacf.com